C-Path and CDISC Announce Therapeutic Area User Guide for Duchenne Muscular Dystrophy October 18, 2017 TUCSON, Ariz., and AUSTIN, Texas – October 18, 2017 –Critical Path Institute (C-Path) and The
Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial simulator for Alzheimer disease (AD) Burton, J., et al.; “Data sharing and standardization to expand a patient-level database of a regulatory-endorsed clinical trial
Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomarkers Conrado, D.J., et al.; “Model-informed biomarker qualification: Alzheimer disease (AD) and Parkinson disease (PD) imaging biomar
Critical Path Innovation Meeting On September 14, 2017, Critical Path Institute’s (C-Path) Patient-Reported Outcome (PRO) Consortium and Electronic Patient-Repor
September 22, 2017 Biometric Monitoring Devices for Objective Assessments of Relevant Endpoints for Clinical Drug Trials: Key Considerations in Developing an Actionable Eco-system
C-Path, CHDI Foundation, and CDISC Announce Public Review Period for Huntington’s Disease Therapeutic Area User Guide September 11, 2017 TUCSON, AZ, NEW YORK, NY, and AUSTIN, TX – September 11, 2017 – Critical Path Institute (C-Pa